← Back to all trials
Completed
NCT03901807
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Conditions: Septic Shock, Endotoxemia
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 157
Sponsor: Spectral Diagnostics (US) Inc.
Location: University of Alabama at Birmingham Birmingham Alabama
Summary
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years of age
2. Hypotension requiring vasopressor support: Requirement for at least one of the vasopressors listed below, at the dose shown below, for at least 2 continuous hours and no more than 30 hours
1. Norepinephrine \> 0.05mcg/kg/min
2. Dopamine \> 10 mcg/kg/min
3. Phenylephrine \> 0.4 mcg/kg/min
4. Epinephrine \> 0.05 mcg/kg/min
5. Vasopressin \> 0.03 units/min
6. Vasopressin (any dose) in combination with another vasopressor listed above
3. The subject must have received intravenous fluid resuscitation of a minimum of 30mL/kg administered within 24 hours of eligibility
4. Documented or suspected infection defined as definitive or empiric intravenous antibiotic administration
5. The subject must have a screening multi-organ dysfunction score (MODS) \>9 OR a sequential organ failure assessment (SOFA) \>11, in the event a complete MODS cannot be obtained due to missing measurements
6. Endotoxin Activity Assay between ≥ 0.60 to \
Source: ClinicalTrials.gov (NCT03901807). StuddyBuddy aggregates publicly available trial information.